Cargando…
Identification of Candidate Biomarkers in Malignant Ascites from Patients with Hepatocellular Carcinoma by iTRAQ-Based Quantitative Proteomic Analysis
Almost all the patients with hepatocellular carcinoma (HCC) at advanced stage experience pathological changes of chronic liver cirrhosis, which generally leads to moderate ascites. Recognition of novel biomarkers in malignant ascites could be favorable for establishing a diagnosis for the HCC patien...
Autores principales: | Zhang, Jinyan, Liang, Rong, Wei, Jiazhang, Ye, Jiaxiang, He, Qian, ChunlingYuan, Ye, Jiazhou, Li, Yongqiang, Liu, Zhihui, Lin, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174818/ https://www.ncbi.nlm.nih.gov/pubmed/30345303 http://dx.doi.org/10.1155/2018/5484976 |
Ejemplares similares
-
i-Tracker: For quantitative proteomics using iTRAQ™
por: Shadforth, Ian P, et al.
Publicado: (2005) -
Quantitative proteomic analysis by iTRAQ(® )for the identification of candidate biomarkers in ovarian cancer serum
por: Boylan, Kristin LM, et al.
Publicado: (2010) -
MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysis
por: Du, Li, et al.
Publicado: (2022) -
iTRAQ and PRM-based quantitative proteomics in early recurrent spontaneous abortion: biomarkers discovery
por: Cui, Ying, et al.
Publicado: (2019) -
Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics
por: Guo, Jiao, et al.
Publicado: (2017)